Nicholas C. Smith was named Chief Financial Officer and Chief Business Officer of Alto Neuroscience, Inc. As of November 6, 2026, Alto Neuroscience, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 28, 2026 to August 27, 2026, naming 3 appointments (Form 8-K, August 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Alto Neuroscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Alto Neuroscience, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-28 to 2026-08-27. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Alto Neuroscience, Inc. files it.
Also on the record for Alto Neuroscience, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.02% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Sirenia Capital Management LP | 6.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | 2.2% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 6% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by EcoR1 Capital, LLC | 5.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 7.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Steven A. Cohen | 3.7% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | 6.5% of the class | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.94% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Vestal Point Capital, LP | 8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Alto Neuroscience, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Alto Neuroscience, Inc. and the records around it.
Alto Neuroscience, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Form D filing Oct 2025
- Who owns it
Companies that share a holder
- K2 HealthVentures Equity Trust LLC also filed stake reports on 1 other company: Neumora Therapeutics, Inc. (May 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026), Design Therapeutics, Inc. (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Fulcrum Therapeutics, Inc. (Jun 2026), Eloxx Pharmaceuticals, Inc. (Jun 2026)
Watch Alto Neuroscience, Inc.
Get an email when Alto Neuroscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alto Neuroscience, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Alto Neuroscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alto Neuroscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 22 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-27 | In | Chief Financial Officer and Chief Business Officer | 8-K, 2026-08-27 | ||
| 2026-05-28 | In | Director | 8-K, 2026-05-28 | ||
| 2026-05-28 | In | 8-K, 2026-05-28 |
Who leads Alto Neuroscience, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer and Chief Business Officer: Nicholas C. Smith, appointed (filed 2026-08-27).
- Director: Andrew Miller, appointed (filed 2026-05-28).
New leaders reset buying decisions — get the Full Report on Alto Neuroscience, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer and Chief Business Officer at Alto Neuroscience, Inc., with the record behind each one.
Find candidates like Chief Financial Officer and Chief Business Officer at Alto Neuroscience, Inc.Every change, in the filing's words
Appointed: Nicholas C. Smith, Chief Financial Officer and Chief Business Officer
On August 26, 2026 (the " Effective Date" ), the Board of Directors (the " Board ") of Alto Neuroscience, Inc. (the " Company ") promoted Nicholas C. Smith, the Company's Chief Financial Officer and Chief Business Officer, to the position of President and Chief Financial Officer, effective immediately.
- In connection with Mr. Smith's promotion, as of August 26, 2026, Amit Etkin, M.D., Ph.D., the Company's President and Chief Executive Officer, continues in his role as the Company's Chief Executive Officer, but no longer holds the office of the President.
- Dr. Etkin serves as the Company's principal executive officer and Mr. Smith serves as the Company's principal financial officer.
- In connection with Mr. Smith's promotion to President and Chief Financial Officer, on the Effective Date, the Company entered into a promotion and retention agreement (the "Promotion and Retention Agreement") with Mr. Smith.
- Pursuant to the Promotion and Retention Agreement, the Company has agreed to pay Mr. Smith a cash retention payment (the "Retention Payment") which shall be paid as follows: (1) $3,000,000 payable within ten days of the Effective Date and (2) $3,000,000 payable on the twelve-month anniversary of the Effective Date.
- Both portions of the Retention Payment are subject to standard deductions and withholdings.
- If, prior to the Retention Date, the Company terminates Mr. Smith's employment without Cause, or his employment terminates due to his death or Disability (as such term is defined in the Offer Letter), the Company will pay to Mr. Smith any unpaid portion of the Retention Payment upon such termination.
Appointed: Andrew Miller, Director
Appointment of Andrew Miller, Ph.D. to the Board On May 27 , 2026, the Board of Directors (the "Board") of Alto Neuroscience, Inc. (the "Company"), following the recommendation of the Board's Nominating and Corporate Governance Committee (the "NCGC"), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.
Appointed: Andrew Miller
The Board also appointed Dr. Miller to the NCGC, replacing Christopher Nixon Cox.
- Effective March 16, 2026, the Board had increased its size from six to seven directors, and Dr. Miller will join the board and fill the resulting vacancy.
- Dr. Miller was appointed as a Class III director for a term expiring at the Company's 2027 Annual Meeting of Stockholders.
- The Board has determined that Dr. Miller is "independent" pursuant to the rules of the New York Stock Exchange ("NYSE") and the current rules and regulations of the Securities and Exchange Commission (the "SEC").
- Dr. Miller, age 44, founded Karuna Therapeutics, Inc. (previously Nasdaq: KRTX), a biopharmaceutical company, and most recently served as its President of Research and Development from January 2024 to March 2024 when it was acquired by Bristol Myers Squibb.
- He previously served as Chief Operating Officer of Karuna from August 2018 to January 2024, its President and Chief Executive Officer from July 2016 to August 2018 and as a member of its board of directors from April 2012 to March 2019.
- Prior to that, Dr. Miller held senior and executive level positions at PureTech Health plc, Tal Medical and Entrega, Inc. Dr. Miller has served on the board of directors of Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company, since February 2026.
- He also serves on the board of directors of multiple privately held biotechnology companies.
Tools for this story
Each opens in a new tab, filled in for Alto Neuroscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.